Marfan syndrome affects connective tissue, which helps support structures throughout the body. Its effects can involve the eyes, skeleton, heart and blood vessels. The features differ between people and can appear at different ages. Understanding the condition means bringing together genetic information, clinical examinations and changes over time. MedlinePlus Genetics describes this range of features.
What FBN1 contributes
Marfan syndrome is caused by disease-causing variants in the FBN1 gene. This gene provides instructions for fibrillin-1, a protein that helps form tiny structures called microfibrils. These contribute to the strength and flexibility of connective tissue and help regulate signals involved in tissue growth and repair. MedlinePlus explains the gene and protein.
A gene name alone does not describe the whole condition. FBN1-related features span a broad range, from limited findings to severe disease beginning early in life. This makes the exact clinical picture an essential part of interpreting a genetic result. NHGRI outlines this variability.
Why assessment covers several body systems
Long limbs, slender fingers, loose joints, a curved spine or changes in chest shape can be visible clues. Eye problems may include nearsightedness or displacement of the lens, called ectopia lentis. These findings vary, so a person’s appearance cannot describe all the possible effects of the condition. MedlinePlus lists the characteristic findings.
The aorta is the large artery carrying blood away from the heart. In Marfan syndrome, it can enlarge, and its wall can tear, a complication called dissection. Heart valves can also be affected. These cardiovascular problems explain why assessment extends beyond visible skeletal features. NHGRI describes the cardiovascular involvement.
How genetic testing fits the diagnosis
Clinicians use diagnostic criteria that combine relevant findings and family history. Depending on the presentation, testing may examine FBN1 or a panel of genes for overlapping conditions. Sequencing and tests for missing or duplicated gene segments detect different kinds of changes; laboratory methods and coverage matter. GeneReviews explains diagnostic testing.
A useful discussion therefore asks several connected questions: What did the laboratory find? How was it classified? Does it fit the person’s examination and family history? What remains unresolved? Keeping these questions together helps explain why receiving a laboratory report and completing a clinical assessment are different steps.
What the result means for a family
Marfan syndrome follows autosomal dominant inheritance. A person with the condition has a 50% chance of passing the disease-causing variant to each child. Some people have a newly arising variant and no affected parent. A missing family history therefore does not exclude Marfan syndrome. NHGRI explains inheritance and new variants.
When the familial pathogenic variant is known, testing can help clarify which relatives need assessment and surveillance. Genetic counselling can explain inheritance and reproductive testing options. These conversations address family implications while preserving space for individual choices. GeneReviews discusses evaluation of relatives and counselling.
Established care and the limits of prediction
Established management includes coordinated specialist care, imaging of the aorta, eye examinations, medicines that reduce stress on the aortic wall, and surgery when indicated. Monitoring continues because findings can evolve. Care is based on clinical measurements and circumstances as well as the diagnosis. GeneReviews summarizes management and surveillance.
Research has explored whether particular FBN1 variant types predict severity or treatment response. Findings are not consistent enough to reliably direct an individual’s management from the variant alone. A reported association between a genetic change and an outcome needs stronger evidence before it becomes a dependable care decision. GeneReviews describes these predictive limits.